These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 19557020)
21. Bevacizumab for retinopathy of prematurity. Gilbert CE; Zin A; Darlow B N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898 [No Abstract] [Full Text] [Related]
22. [VEGF antibodies as therapy for retinopathy of prematurity]. Oberacher-Velten IM; Helbig H Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249 [TBL] [Abstract][Full Text] [Related]
23. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity. Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183 [No Abstract] [Full Text] [Related]
24. Bevacizumab for retinopathy of prematurity. Lim LS; Mitchell P; Wong TY N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897 [No Abstract] [Full Text] [Related]
25. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model. Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity. Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D Retina; 2011; 31(7):1239-47. PubMed ID: 21555969 [TBL] [Abstract][Full Text] [Related]
30. Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned? Lim LS; Cheung CMG; Mitchell P; Wong TY Am J Ophthalmol; 2011 Sep; 152(3):329-331. PubMed ID: 21855670 [No Abstract] [Full Text] [Related]
31. A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination. Patel CK; Walker NJ; Kam JK Br J Ophthalmol; 2010 Aug; 94(8):1107-9. PubMed ID: 20558426 [No Abstract] [Full Text] [Related]
32. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Kong L; Mintz-Hittner HA; Penland RL; Kretzer FL; Chévez-Barrios P Arch Ophthalmol; 2008 Aug; 126(8):1161-3. PubMed ID: 18695118 [No Abstract] [Full Text] [Related]
33. Histology of fibrovascular membranes of proliferative diabetic retinopathy after intravitreal injection of bevacizumab. Kubota T; Morita H; Tou N; Nitta N; Tawara A; Satoh H; Shimajiri S Retina; 2010 Mar; 30(3):468-72. PubMed ID: 19952991 [TBL] [Abstract][Full Text] [Related]
34. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab. Goldman DR; Baumal CR J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 23739589 [TBL] [Abstract][Full Text] [Related]
35. Retinal detachment with macular hole following intravitreal bevacizumab in patient with severe proliferative diabetic retinopathy. Mitamura Y; Ogata K; Oshitari T; Asaumi N; Yamamoto S Br J Ophthalmol; 2008 May; 92(5):717-8. PubMed ID: 18441183 [No Abstract] [Full Text] [Related]
36. Is Avastin the right choice of treatment for retinopathy of prematurity? Käll A Acta Paediatr; 2012 Aug; 101(8):796-8. PubMed ID: 22788788 [No Abstract] [Full Text] [Related]
37. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Lalwani GA; Berrocal AM; Murray TG; Buch M; Cardone S; Hess D; Johnson RA; Puliafito CA Retina; 2008 Mar; 28(3 Suppl):S13-8. PubMed ID: 18317338 [TBL] [Abstract][Full Text] [Related]
38. Bevacizumab for retinopathy of prematurity. Good WV; Palmer EA N Engl J Med; 2011 Jun; 364(24):2359; author reply 2361-2. PubMed ID: 21675899 [No Abstract] [Full Text] [Related]